Rezolute shares rose 16.0% to $3.48 after eye medication reached the primary target of the mid-term study
眼病药物达到中期研究的主要目标后Rezolute股价上涨16.0％至3.48美元
Rezolute shares rose 16.0% to $3.48 after eye medication reached the primary target of the mid-term study
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.